Anixa Biosciences Advances Breast Cancer Vaccine Clinical Trial Following Phase 1 Success
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy ANIX?
Source: PRnewswire
- Clinical Trial Success: Anixa Biosciences reported that 74% of participants in its Phase 1 clinical trial for the breast cancer vaccine generated protocol-defined immune responses, demonstrating safety and tolerability at the maximum tolerated dose, which paves the way for advancing to Phase 2 trials.
- Partnership Agreement: Anixa has entered into a development and manufacturing agreement with Cytovance Biologics to produce cGMP clinical materials for its upcoming Phase 2 trial, ensuring high-quality production for the vaccine's development.
- Innovative Vaccine Mechanism: The vaccine targets α-lactalbumin, a protein typically expressed in breast tissue that re-emerges in various breast cancers, aiming to elicit an immune response against this protein, potentially offering both therapeutic and preventive benefits for patients, highlighting its significant clinical application potential.
- Strategic Development Focus: Anixa's CEO emphasized that with positive Phase 1 data, the company is focused on advancing the vaccine program and expects to provide near-term updates on progress, demonstrating its ongoing commitment to cancer immunotherapy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANIX
Wall Street analysts forecast ANIX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.720
Low
10.00
Averages
10.00
High
10.00
Current: 2.720
Low
10.00
Averages
10.00
High
10.00
About ANIX
Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The Company's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The Company is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anixa Biosciences Advances Breast Cancer Vaccine Clinical Trial Following Phase 1 Success
- Clinical Trial Success: Anixa Biosciences reported that 74% of participants in its Phase 1 clinical trial for the breast cancer vaccine generated protocol-defined immune responses, demonstrating safety and tolerability at the maximum tolerated dose, which paves the way for advancing to Phase 2 trials.
- Partnership Agreement: Anixa has entered into a development and manufacturing agreement with Cytovance Biologics to produce cGMP clinical materials for its upcoming Phase 2 trial, ensuring high-quality production for the vaccine's development.
- Innovative Vaccine Mechanism: The vaccine targets α-lactalbumin, a protein typically expressed in breast tissue that re-emerges in various breast cancers, aiming to elicit an immune response against this protein, potentially offering both therapeutic and preventive benefits for patients, highlighting its significant clinical application potential.
- Strategic Development Focus: Anixa's CEO emphasized that with positive Phase 1 data, the company is focused on advancing the vaccine program and expects to provide near-term updates on progress, demonstrating its ongoing commitment to cancer immunotherapy.
See More
Anixa Biosciences Advances Cancer Therapy with Lira-cel Trial Update
- Clinical Trial Progress: Anixa Biosciences' ongoing Phase 1 trial for ovarian cancer CAR-T therapy will be presented by principal investigator Dr. Robert Wenham at the Society of Gynecologic Oncology Annual Meeting from April 10-13, 2026, highlighting the company's commitment to advancing cancer treatment.
- Targeted Therapy Innovation: The lira-cel therapy uniquely targets the follicle-stimulating hormone receptor (FSHR), selectively expressed in ovarian cells and tumor vasculature, potentially offering new treatment options for recurrent ovarian cancer patients, thereby improving survival rates and quality of life.
- Collaborative R&D Advantage: Anixa's partnership with Moffitt Cancer Center leverages innovative CAR-T technology, showcasing the company's leadership in cancer immunotherapy while laying the groundwork for future treatment developments and enhancing market competitiveness.
- Vaccine Development Outlook: Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancers, demonstrating the company's extensive positioning across various cancer treatment areas, aiming to address multiple intractable cancers through immunotherapeutic approaches.
See More
Anixa Biosciences Updates on CAR-T Therapy Progress
- Clinical Trial Progress: Anixa Biosciences' ongoing Phase 1 trial for ovarian cancer CAR-T therapy is actively enrolling adult women with recurrent ovarian cancer who have undergone at least two prior therapies, demonstrating the company's commitment to innovative cancer treatments.
- Key Conference Presentation: Dr. Robert Wenham from Moffitt Cancer Center will present the clinical trial design and objectives of lira-cel at the Society of Gynecologic Oncology Annual Meeting from April 10-13, 2026, which is expected to enhance Anixa's visibility among global oncology experts.
- Technological Innovation: Lira-cel utilizes a unique chimeric endocrine receptor-T cell (CER-T) technology that specifically targets ovarian cells and tumor vasculature, potentially offering new treatment options for recurrent ovarian cancer patients, highlighting Anixa's leading position in biotechnology.
- Strategic Partnerships: Anixa's collaboration with Moffitt Cancer Center combines expertise to advance cancer immunotherapy, reflecting the company's strategic investments and long-term commitment to cancer treatment advancements.
See More
Anixa Biosciences CEO Discusses Cancer Vaccine Progress on Podcast
- Clinical Trial Progress: Anixa Biosciences has reported positive data from clinical trials of its breast cancer vaccine and ovarian cancer CAR-T therapy, indicating potential therapeutic benefits that may enhance future funding and partnership opportunities.
- Technological Innovation: The ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center utilizes a novel CAR-T technology that directly targets tumor cells via the natural ligand FSH binding to the FSHR receptor, showcasing significant differentiation from traditional therapies.
- Vaccine Development Collaboration: Anixa's partnership with Cleveland Clinic focuses on vaccines for treating and preventing breast and ovarian cancers, as well as addressing various intractable cancers like lung, colon, and prostate cancers, highlighting its extensive market potential.
- Business Model Advantage: Anixa's unique business model, which involves collaboration with world-renowned research institutions at all stages of development, ensures continuous exploration of emerging technologies, thereby enhancing its competitive edge in the biotechnology sector.
See More
Anixa Biosciences CEO Discusses Cancer Vaccine Progress on Podcast
- Clinical Trial Progress: Anixa Biosciences has reported positive data from clinical trials of its breast cancer vaccine and ovarian cancer CAR-T therapy, indicating potential therapeutic benefits that could enhance the company's market performance in the future.
- Collaborative R&D Model: The partnership with Moffitt Cancer Center to develop ovarian cancer immunotherapy using innovative CAR-T technology highlights Anixa's leading position in cancer treatment, which may attract increased investor interest.
- Vaccine Portfolio Expansion: The company's collaboration with Cleveland Clinic to develop vaccines for breast and ovarian cancer, along with additional vaccines targeting hard-to-treat cancers like lung, colon, and prostate cancer, demonstrates significant market potential.
- Financial Condition Discussion: During the podcast, CEO Dr. Amit Kumar addressed the company's financial condition and future plans, reflecting a commitment to ongoing innovation and market expansion that could bolster investor confidence.
See More
Anixa Biosciences Secures Patent Allowance in South Korea
- Patent Allowance Granted: Anixa Biosciences announced that the Korean Ministry of Intellectual Property has issued a Notice of Allowance for its breast cancer vaccine platform, exclusively licensed from Cleveland Clinic, marking a significant advancement in the company's global intellectual property expansion.
- Patent Content Protection: The patent, titled 'Vaccine Adjuvants and Formulations,' provides composition of matter protection in South Korea, further complementing Anixa's existing patents in the U.S. and other jurisdictions, thereby enhancing its competitive position in the market.
- Commercialization Potential: This patent approval not only supports Anixa's global intellectual property expansion but also lays the groundwork for potential commercialization efforts outside the United States, which could lead to new revenue streams for the company.
- Market Reaction: Anixa's stock fell 1.75% in premarket trading to $2.8, reflecting market caution regarding its vaccine development progress, despite the patent allowance presenting new growth opportunities for the company.
See More
Anixa Biosciences Advances Breast Cancer Vaccine Clinical Trial Following Phase 1 Success
- Clinical Trial Success: Anixa Biosciences reported that 74% of participants in its Phase 1 clinical trial for the breast cancer vaccine generated protocol-defined immune responses, demonstrating safety and tolerability at the maximum tolerated dose, which paves the way for advancing to Phase 2 trials.
- Partnership Agreement: Anixa has entered into a development and manufacturing agreement with Cytovance Biologics to produce cGMP clinical materials for its upcoming Phase 2 trial, ensuring high-quality production for the vaccine's development.
- Innovative Vaccine Mechanism: The vaccine targets α-lactalbumin, a protein typically expressed in breast tissue that re-emerges in various breast cancers, aiming to elicit an immune response against this protein, potentially offering both therapeutic and preventive benefits for patients, highlighting its significant clinical application potential.
- Strategic Development Focus: Anixa's CEO emphasized that with positive Phase 1 data, the company is focused on advancing the vaccine program and expects to provide near-term updates on progress, demonstrating its ongoing commitment to cancer immunotherapy.
See More
Anixa Biosciences Advances Cancer Therapy with Lira-cel Trial Update
- Clinical Trial Progress: Anixa Biosciences' ongoing Phase 1 trial for ovarian cancer CAR-T therapy will be presented by principal investigator Dr. Robert Wenham at the Society of Gynecologic Oncology Annual Meeting from April 10-13, 2026, highlighting the company's commitment to advancing cancer treatment.
- Targeted Therapy Innovation: The lira-cel therapy uniquely targets the follicle-stimulating hormone receptor (FSHR), selectively expressed in ovarian cells and tumor vasculature, potentially offering new treatment options for recurrent ovarian cancer patients, thereby improving survival rates and quality of life.
- Collaborative R&D Advantage: Anixa's partnership with Moffitt Cancer Center leverages innovative CAR-T technology, showcasing the company's leadership in cancer immunotherapy while laying the groundwork for future treatment developments and enhancing market competitiveness.
- Vaccine Development Outlook: Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancers, demonstrating the company's extensive positioning across various cancer treatment areas, aiming to address multiple intractable cancers through immunotherapeutic approaches.
See More
Anixa Biosciences Updates on CAR-T Therapy Progress
- Clinical Trial Progress: Anixa Biosciences' ongoing Phase 1 trial for ovarian cancer CAR-T therapy is actively enrolling adult women with recurrent ovarian cancer who have undergone at least two prior therapies, demonstrating the company's commitment to innovative cancer treatments.
- Key Conference Presentation: Dr. Robert Wenham from Moffitt Cancer Center will present the clinical trial design and objectives of lira-cel at the Society of Gynecologic Oncology Annual Meeting from April 10-13, 2026, which is expected to enhance Anixa's visibility among global oncology experts.
- Technological Innovation: Lira-cel utilizes a unique chimeric endocrine receptor-T cell (CER-T) technology that specifically targets ovarian cells and tumor vasculature, potentially offering new treatment options for recurrent ovarian cancer patients, highlighting Anixa's leading position in biotechnology.
- Strategic Partnerships: Anixa's collaboration with Moffitt Cancer Center combines expertise to advance cancer immunotherapy, reflecting the company's strategic investments and long-term commitment to cancer treatment advancements.
See More
Anixa Biosciences CEO Discusses Cancer Vaccine Progress on Podcast
- Clinical Trial Progress: Anixa Biosciences has reported positive data from clinical trials of its breast cancer vaccine and ovarian cancer CAR-T therapy, indicating potential therapeutic benefits that may enhance future funding and partnership opportunities.
- Technological Innovation: The ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center utilizes a novel CAR-T technology that directly targets tumor cells via the natural ligand FSH binding to the FSHR receptor, showcasing significant differentiation from traditional therapies.
- Vaccine Development Collaboration: Anixa's partnership with Cleveland Clinic focuses on vaccines for treating and preventing breast and ovarian cancers, as well as addressing various intractable cancers like lung, colon, and prostate cancers, highlighting its extensive market potential.
- Business Model Advantage: Anixa's unique business model, which involves collaboration with world-renowned research institutions at all stages of development, ensures continuous exploration of emerging technologies, thereby enhancing its competitive edge in the biotechnology sector.
See More
Anixa Biosciences CEO Discusses Cancer Vaccine Progress on Podcast
- Clinical Trial Progress: Anixa Biosciences has reported positive data from clinical trials of its breast cancer vaccine and ovarian cancer CAR-T therapy, indicating potential therapeutic benefits that could enhance the company's market performance in the future.
- Collaborative R&D Model: The partnership with Moffitt Cancer Center to develop ovarian cancer immunotherapy using innovative CAR-T technology highlights Anixa's leading position in cancer treatment, which may attract increased investor interest.
- Vaccine Portfolio Expansion: The company's collaboration with Cleveland Clinic to develop vaccines for breast and ovarian cancer, along with additional vaccines targeting hard-to-treat cancers like lung, colon, and prostate cancer, demonstrates significant market potential.
- Financial Condition Discussion: During the podcast, CEO Dr. Amit Kumar addressed the company's financial condition and future plans, reflecting a commitment to ongoing innovation and market expansion that could bolster investor confidence.
See More
Anixa Biosciences Secures Patent Allowance in South Korea
- Patent Allowance Granted: Anixa Biosciences announced that the Korean Ministry of Intellectual Property has issued a Notice of Allowance for its breast cancer vaccine platform, exclusively licensed from Cleveland Clinic, marking a significant advancement in the company's global intellectual property expansion.
- Patent Content Protection: The patent, titled 'Vaccine Adjuvants and Formulations,' provides composition of matter protection in South Korea, further complementing Anixa's existing patents in the U.S. and other jurisdictions, thereby enhancing its competitive position in the market.
- Commercialization Potential: This patent approval not only supports Anixa's global intellectual property expansion but also lays the groundwork for potential commercialization efforts outside the United States, which could lead to new revenue streams for the company.
- Market Reaction: Anixa's stock fell 1.75% in premarket trading to $2.8, reflecting market caution regarding its vaccine development progress, despite the patent allowance presenting new growth opportunities for the company.
See More
